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1  | INTRODUC TION
Frailty is an emerging indicator of poor outcomes in solid organ trans‐
plantation. This is particularly true in the context of liver transplanta‐
tion where mounting evidence has linked several measures of frailty 
with delisting and mortality.1‒7 Reflecting factors unaccounted for 
by the Model for End‐Stage Liver Disease (MELD), tools that mea‐
sure frailty quantify the patient’s physiologic reserve. Frailty tools 
measure many features, including disability (ie, activities of daily 
living),5,8 physical function (ie, handgrip, walk speed),9 and muscle 
bulk/sarcopenia (ie, psoas size or morphomics).10,11 The most widely 
utilized frailty tool in solid organ transplantation, the Fried Frailty 
Index (FFI), aggregates multiple domains of frailty. These include 
subjective report of exhaustion, weight loss, and physical activity as 
well as objectively measured walk speed and handgrip.12 Beyond risk 
assessment, a diagnosis of frailty should trigger interventions aimed 
at restoring function. Indices such as the FFI are helpful; however, to 
guide therapy, it is important to define each patient’s unique drivers 
of frailty.
A patient with cirrhosis can be frail for many reasons. These 
include aging, comorbidities, malnutrition, deconditioning, severe 
liver failure, and cognitive impairment. When present, hepatic en‐
cephalopathy (HE), likely plays a critical role in frailty. HE is caused 
in part by hyperammonemia, a potent driver of muscle catabolism 
which leads to weakness and sarcopenia.13,14 Further, the symptoms 
of HE exacerbate frailty: anorexia compounds malnutrition and sar‐
copenia,15 poor coordination leads to falls, and hospitalization for HE 
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Frailty is increasingly recognized as a predictor of poor outcomes in solid organ trans‐
plantation. The most widely utilized frailty tool, the Fried Frailty Index (FFI), includes 
patient‐reported exhaustion, weight loss, and physical activity as well as measured 
walk speed and handgrip. Although hepatic encephalopathy (HE) is common among 
liver transplant candidates, data are lacking regarding its impact on the interpretation 
of frailty. We prospectively enrolled 685 patients with cirrhosis during their trans‐
plant evaluation, following them until death or transplantation. Our cohort was aged 
54.5 ± 10.3 years, 60% male, with an average MELD score of 14.7 ± 6.3. A history of 
HE was present in 39%. Frailty was present in 41%, associated with higher MELD, low 
albumin, ascites, and HE. HE was associated with frail performance on three compo‐
nents of the FFI‐grip (odds ratio 1.41 95% CI, 1.03‐1.92), walk speed (1.56 95% CI, 
1.14‐2.15), and decreased energy (1.44 95% CI, 1.05‐1.99). These three components 
were associated with transplant free survival in the whole cohort: energy (hazard 
ratio 1.67 95% CI, 1.25‐2.28), grip (1.63 95% CI, 1.24‐2.16), and walk speed (1.56 95% 
CI, 1.19‐2.04). However, among patients with HE, the FFI was not associated with 
survival. HE plays a critical role in the frailty phenotype and the implications of frailty 
among patients with cirrhosis evaluated for liver transplantation.
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worsens physical decline. Despite a plausible relationship between 
HE and frailty, data are limited regarding how HE impacts both the 
frailty phenotype and the outcomes reported to be associated with 
frailty. Herein, we assessed the association between HE, frailty, and 
clinical outcomes in a prospective cohort study of frailty among liver 
transplant candidates.
2  | METHODS
Adult (age ≥18 years) patients with cirrhosis were prospectively 
enrolled in an observational cohort study from the liver trans‐
plant clinic of the University of Michigan Hospital from July 24, 
2009 to February 15, 2015. Informed consent in writing was ob‐
tained from each patient following approval by the Institutional 
Review Board of the University of Michigan Medical School. As 
reported previously, 31% of patients referred for transplant evalu‐
ation over the study period were included in this study (mainly 
due to variable availability of research coordinators).16 Of the 830 
patients enrolled, our sample for this study included 685 partici‐
pants with only one patient lost to follow‐up and 143 with miss‐
ing data (mainly related to completing all elements of the frailty 
assessment). Results of the study were blinded to the transplant 
care teams during the study period. A baseline evaluation included 
demographic and clinical details with a laboratory assessment to 
determine the MELD score and serum albumin. The presence of 
HE was defined by a history of overt HE and/or the current use 
of medical therapy for HE (lactulose or rifaximin). We also further 
stratified by the intensity of therapy at the time of evaluation 
(lactulose, rifaximin, or both). The presence of ascites was defined 
by either medical therapy for or radiographic evidence of intra‐
peritoneal fluid. Frailty was also assessed using the FFI performed 
in clinic by trained research assistants. Previously validated cut‐
offs for frailty by each of the above numerated components were 
applied to assign binary values for frailty for each component. 
Overall frailty was considered as a score of frail for three or more 
components.12 Enrolled patients were then followed until the con‐
clusion of data collection (May 1, 2016) for outcomes that included 
liver transplantation and death.
2.1 | Analysis
The primary outcome of interest was transplant‐free survival, using 
Cox proportional hazards regression and adjusting for MELD score, 
ascites, and serum albumin. The principle exposure of interest was 
the FFI and its components in subsamples stratified by the presence 
(or absence) of HE. Sensitivity tests were performed for the vary‐
ing intensities of HE therapies at the time of enrollment. Variables 
significantly associated with frailty were further explored using 
 logistic regression to determine their impact on the FFI components 
in a logistic regression. Student t tests and Wilcoxon rank sum tests 
were used to compare differences in continuous variables between 
groups according to the normality of data categorical variables were 
compared using Fisher’s exact tests. Significance was determined if 
a two‐tailed P‐value was <.05.
3  | RESULTS
Table 1 details the sample characteristics overall and according to 
the presence of frailty. In general, our sample was aged an average of 
55 years, 60% male, and relatively free of cardiopulmonary comorbidi‐
ties. By contrast, most patients were decompensated with a history of 
ascites (374/55%) or HE (268/39%), 203 (30%) of whom presented with 
both. At the time of evaluation, 153 (57%) were actively taking ther‐
apy (lactulose or rifaximin) for HE. Of these patients, 65 were taking 
lactulose monotherapy and 57 were taking combination lactulose and 
rifaximin. Twelve patients had transjugular intrahepatic portosystemic 
shunts at the time of evaluation. Clinical characteristics were balanced 
with respect to the presence of frailty save for MELD scores (higher 
with frailty), albumin concentrations (lower with frailty), and decom‐
pensations (more common with frailty).
The clinical associations with frailty as determined by perfor‐
mance measures are examined further in Table 2. MELD, albumin, 
HE, and ascites were all associated with frail walk speeds while only 
albumin and HE were associated with frail handgrip. Each variable 
with the exception of ascites was linked to frail energy expenditure 
while HE was the only variable not associated with frail activity. 
Ascites was the only variable associated with weight loss. We also 
repeated these analyses for the subgroups of patients with prior 
HE based on the intensity of HE therapy at the time of enrollment 
(Table S1).
In follow‐up, 320 (47%) patients were waitlisted at our center, 228 
(33%) patients died, and 136 patients (20%) received a liver trans‐
plant after a median of 76 IQR (19‐198) days. Overall transplant‐free 
 survival was 659 IQR (208‐1472) days. The variables associated with 
decreased survival were higher MELD, lower albumin, ascites, HE, 
and frailty (FFI ≥ 3). Placement on the waiting list for liver transplan‐
tation was associated with MELD (higher MELD, higher likelihood), al‐
bumin (lower albumin, lower likelihood), and frailty (lower likelihood).
After adjusting for MELD, albumin, and ascites, the specific com‐
ponents of the FFI that were linked with transplant‐free survival were 
energy (HR 1.67 95% CI, 1.25‐2.28), grip (HR 1.63 95% CI, 1.24‐2.16), 
and walk speed (HR 1.56 95% CI, 1.19‐2.04). In Figure 1, we show the 
impact of each component of frailty as well as the overall frailty score 
(out of 5) on transplant‐free survival in patients with and without HE. 
Adjusting for MELD, albumin, and the presence of ascites, frailty scores 
were significantly associated with death for patients without HE but not 
in patients with HE. In patients without HE, walk speed, handgrip, and 
energy expenditure were the three components of frailty associated 
with mortality. These findings are present in patients who are on any 
therapy for HE; however, for patients not currently on therapy there is 
a notable difference. While frailty overall was not associated with mor‐
tality in patients with prior HE, frail walk speed did predict increased 
mortality in the cohort of patients with HE who were not on therapy at 
the time of enrollment (HR 1.51 95% CI, 1.07‐2.12) (Figure S1).
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4  | DISCUSSION
Within the field of solid organ transplantation, the presence of HE 
raises unique questions regarding the interpretation and manage‐
ment of frailty specific to patients with cirrhosis evaluated for liver 
transplant. The relative contribution of HE to the frailty phenotype 
with respect to other factors is unclear. These data from a prospec‐
tive cohort study of 685 patients evaluated for liver transplantation 
show that although HE increases the risk of frailty, frailty is not as‐
sociated with mortality in patients with HE.
There are two principle implications of these findings. First, 
HE is associated with frailty. Frailty—like HE—is a biomarker of 
diminished physiologic reserve, both of which are linked to  adverse 
outcomes. HE and frailty share similar associations: poor patient‐
reported outcomes,15 sarcopenia,13,14 poor coordination (and 
falls),8,17 and hospitalization.18 However, given that the pathophys‐
iology of hyperammonemia and HE cause many of these factors 
which would be captured clinically as frailty, HE is a crucial step in 
the causal pathway of frailty among patients with advanced liver 
disease.
Interventions for frailty should be multimodal with attention paid to 
enhanced nutrition, physical training, and cognitive function.19 In many 
cases, these modalities are simultaneously effective for the treatment of 
HE. Although further research is needed to determine if HE‐related frailty 
Overall (N = 685)
Non‐frail 
(n = 406) Frail (n = 279) P‐value
Age 54.5 ± 10.3 54.2 ± 10.5 54.8 ± 10.0 .42
Male 409 (60%) 247 (61%) 162 (59%) .58
Non‐white 96 (14%) 55 (14%) 41 (15%) .65
Major etiologies
Hepatitis C 156 (23%) 97 (24%) 59 (21%)
Alcohol 166 (24%) 92 (23%) 74 (27%)
NASH 157 (23%) 90 (22%) 67 (24%) .27
Body mass index 29.6 ± 7.1 29.6 ± 6.5 29.6 ± 7.9 .88
Congestive heart 
failure
14 (2%) 9 (2%) 5 (2%) .79
Chronic obstructive 
pulmonary disease
32 (5%) 14 (3%) 18 (7%) .10
Diabetes mellitus 199 (29%) 111 (28%) 88 (32%) .23
Coronary artery 
disease
32 (5%) 17 (4%) 15 (5%) .47
Dialysis 17 (2%) 9 (2%) 8 (3%) .62
MELD 14.7 ± 6.3 13.4 ± 5.2 16.5 ± 7.3 <.0001
Albumin (g/dL) 3.2 ± 0.7 3.3 ± 0.7 3.0 ± 0.7 <.0001
Hepatic 
encephalopathy
268 (39%) 144 (35%) 124 (44%) .02
Ascites 374 (55%) 204 (50%) 170 (61%) .006
dL, deciliter; MELD, Model for End‐stage Liver Disease; NASH, nonalcoholic steatohepatitis. Frailty 
is defined by a Fried Frailty Index of 3 or greater.
Continuous variables are presented as mean ± standard deviation.
TA B L E  1   Demographics and clinical 
characteristics
TA B L E  2   The impact of clinical predictors on frailty determination
Grip Walk speed Weight loss Energy Activity
Odds ratio of being classified as frail (95% CI)
MELD (per unit) 1.01 (0.99‐1.04) 1.08 (1.06‐1.11) 1.02 (0.99‐1.05) 1.07 (1.04‐1.10) 1.07 (1.05‐1.10)
Albumin (per g/dL) 1.29 (1.03‐1.61) 2.0 (1.56‐2.57) 0.98 (0.77‐1.25) 1.95 (1.53‐2.49) 1.59 (1.26‐2.02)
Hepatic 
encephalopathy
1.41 (1.03‐1.92) 1.56 (1.14‐2.15) 0.94 (0.68‐1.32) 1.44 (1.05‐1.99) 1.13 (0.83‐1.56)
Ascites 1.18 (0.87‐1.60) 1.53 (1.12‐2.11) 1.40 (1.01‐1.95) 1.29 (0.95‐1.75) 1.52 (1.11‐2.07)
CI, confidence interval; dL, deciliter; MELD, Model for End‐Stage Liver Disease.
The association of clinical variables and performance scored as frail for each component of the Fried Index is presented as the results of a logistic 
 regression. A confidence interval that does not cross 1.0 is our criterion for statistical significance.
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is reversible, there is evidence that therapy can improve aspects of the HE 
phenotype that are consistent with frailty. These include improvements 
after HE therapy of poor patient‐reported outcomes,20 coordination (in a 
driving simulator),21 and, although it has been studied only in preclinical 
models, ammonia‐lowering therapy may reverse ammonia‐induced sarco‐
penia.14 Additionally, at a minimum, owing to the adverse impact of sarco‐
penia on frailty and waitlist mortality and the salutary effect of improved 
nutrition on HE, protein intake should be increased in patients with HE to 
1.25 g/kg ideal bodyweight.22 Further study of the role of screening tests 
for subclinical HE on longitudinal assessments of frailty, potentially by using 
point‐of‐care tests such as the EncephalApp Stroop,23,24 are warranted.
Second, we found that the components of the FFI that are asso‐
ciated with mortality (energy, grip, walk speed) are identical to those 
associated with HE. Whereas others have shown that patients with 
HE report more subjective disability5 and worse patient‐reported 
outcomes (including poor balance),15 these data highlight a global 
impact of HE on frailty measures. At the same time, among patients 
actively receiving therapy for HE, the impact of HE on survival ap‐
pears equivalent to frailty’s impact on survival for patients without 
HE. Three large studies (two from one center3,25) have examined and 
confirmed the predictive value of the FFI on mortality in the pre‐
transplant setting.3,19,25 However, these studies did not evaluate the 
impact of HE on FFI. To avoid the pitfalls of subjective assessments 
of frailty, the field of liver transplantation may be moving toward the 
strictly objective measures such as the Liver Frailty Index (handgrip, 
chair stands, and balance).8 However, our data show that the rel‐
ative impact of HE and cognitive dysfunction will not diminish for 
objective measures and will need to be addressed even as our frailty 
indices improve and become more standardized.
These data must be interpreted in the context of study design. 
First, we neither directly analyzed cognitive function nor did we 
directly measure sarcopenia for correlation with frailty. The spe‐
cific underlying mechanism of HE’s impact on frailty in this work is 
therefore speculative and ought to be evaluated in future studies by 
testing for sarcopenia and cognitive dysfunction. Further, because 
we did not evaluate cognitive function at the time of enrollment, 
we cannot know whether patients with prior HE who were not on 
therapy were more cognitively intact than those, for example, on 
combination therapy. Second, we do not evaluate the duration or 
trajectory of our patients’ frailty which would speak to physiologic 
reserve and potential for reversibility. Worsening frailty may be as‐
sociated with increased mortality and additional data are needed 
to determine whether HE is as associated with a specific trajectory. 
Third, independent of HE, cirrhotic complications can contribute to 
diminished cognitive reserve, or the ability to preserve cognitive 
function in the context of a neurological insult. Decreased cognitive 
reserve is associated with poor health‐related quality of life which 
could be a driver of the subjective components of the FFI.26 Fourth, 
though this cohort of 268 patients with HE is the largest evaluated 
for the presence of frailty to date, we cannot exclude the possibility 
that an effect of frailty on mortality would be observed in a larger 
sample. Finally, we did not evaluate indices of frailty other than the 
FFI and future studies, particularly those that measure cognitive 
function directly, should include the liver frailty index.8
In conclusion, as data on frailty accrue, efforts to understand 
the underlying mechanisms of frailty are essential for the interpre‐
tation of its impact and to inform therapeutic strategies. Our data 
suggest that HE appears to be an important determinant of both 
F I G U R E  1   Frailty is not predictive of transplant‐free survival in patients with hepatic encephalopathy. This figure delineates the 
association of frailty with transplant‐free survival in patients without (panel A) and with (panel B) hepatic encephalopathy. While three 
components of the Fried Frailty Index are significantly predictive of survival in patients without encephalopathy, none are for patients with 
encephalopathy. Hazard ratios are presented with 95% confidence intervals (CI) with a dashed line to indicate 1.0; intervals that cross 1.0 are 
not significant. All estimates are adjusted for Model for End‐Stage Liver Disease Score, albumin concentration, and the presence of ascites
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the frailty phenotype and adverse health outcomes associated 
with frailty. Given that HE is responsive to pharmacological and 
nutritional therapy, prospective study of HE‐directed treatment 
for frail patients with cirrhosis is indicated.
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